The COPD therapeutics market is expected to increase steadily and reach a value of US$ 20,035.5 Million by 2033. From its market value of US$ 12,144.1 million in 2023, this represents a notable increase, indicating a compound annual growth rate (CAGR) of 5.1% for the projection period.
Concerning Increase in COPD Cases Driving Market Expansion
The alarming rise in COPD incidence globally is the main factor propelling the market for COPD treatments. This increase can be ascribed to elements such as:
Increased Smoking Rates: Since smoking is still one of the main causes of COPD and isn’t predicted to significantly diminish in some areas, it is anticipated that the COPD burden would rise.
Genetic Predisposition: A subset of patients may be more susceptible to COPD due to specific genetic causes.
Advance Insights With Your Report Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-4337
Surgical Procedures for Serious Instances:
Surgery might be advised in COPD instances that are very severe. Treatment options include lung volume reduction surgery, lung transplants, and bullectomies. To stop the disease’s progression and enhance patient outcomes, appropriate therapeutic care is crucial, as evidenced by the high prevalence of COPD.
- Combination Therapies Are Becoming More Popular
The market for COPD treatments is seeing an increase in patients’ preference for combination treatments over single prescriptions, or monotherapy. LABA-ICS (long-acting beta antagonist and inhaled corticosteroid) and LAMA-ICS (long-acting muscarinic antagonist and inhaled corticosteroid) are two examples of combination therapy that have the following benefits:
Enhanced Effectiveness: When it comes to controlling COPD symptoms and raising patients’ quality of life, combination treatments work better than monotherapy.
Better Patient Outcomes: Combination medications provide a more successful treatment strategy for patients who do not respond well to bronchodilators or corticosteroids alone, which may increase demand for COPD therapeutics.
Key players:
- Pfizer Inc.
- Adamis Laboratories Inc.
- GlaxoSmithKline plc.
- AstraZeneca
- Merk & Co.
- Novartis AG
- Mylan N.V.
- Teva Pharmaceutical Industries
Our Methodology Overview:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-4337
Key Segments Profiled in the COPD Therapeutics Industry Survey
By Component:
- COPD Therapeutics Drug Class
- Bronchodilators
- Steroids
- Phosphodiesterase-4 inhibitors
- Theophylline
- Antibiotics
- COPD Therapeutics Delivery Systems
- Oral
- Inhalation
By End User:
- Hospitals
- Private Clinics
- Outpatient Departments
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Discover Extensive Market Analysis: Purchase Now to Access: https://www.futuremarketinsights.com/checkout/4337
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
